NewsBenzingaReported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease Benzinga 2026.11.09 08:38 (GMT+0) Open on Benzinga Other news David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Bernstein Maintains Market Perform on Tyson Foods, Raises Price Target to $72 Broadcom Stock Is Up Tuesday: AI Chip Diversification, Dec. 9 Earnings, Analyst Targets Bernstein Downgrades PepsiCo to Underperform, Lowers Price Target to $128 If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today What's Going On With Ouster Stock Tuesday?